Expression and Possible Prognostic Role of MAGE-A4, NY-ESO-1, and HER-2 Antigens in Women with Relapsing Invasive Ductal Beast Cancer: Retrospective Immunohistochemical Study

Bandić, Daniela; Juretić, Antonio; Šarčević, Bošena; Šeparović, Viktor; Tiljak, Kujundžić Mirjana; Hudolin, Tvrtko; Spagnoli, Giulio C.; Čović, Dinko; Šamija, Mirko
February 2006
Croatian Medical Journal;2006, Vol. 47 Issue 1, p32
Academic Journal
Aim To evaluate the possible prognostic role of the expression of MAGE-A4 and NY-ESO-1 cancer/testis antigens in women diagnosed with invasive ductal breast cancer and determine the expression of HER-2 antigen. Methods The expression of MAGE-A4, NY-ESO-1, and HER-2 antigens was evaluated immunohistochemically on archival paraffin-embedded samples of breast cancer tissue from 81 patients. All patients had T1 to T3, N0 to N1, M0 tumors and underwent postoperative radiotherapy and, if indicated, systemic therapy (chemotherapy and hormonal therapy). The antigen expression in women who were disease-free for 5 years of follow up (n = 23) was compared with that in women with either locoregional relapse (n = 30) or bone metastases (n = 28). Patient survival after 10 years of follow up was assessed. Results The three groups of women were comparable in terms of age, type of operation, tumor size, tumor grade, number of metastatically involved axillary lymph nodes, Nottingham prognostic index (NPI), progesterone receptor (PR) status, and adjuvant hormonal therapy. Estrogen receptors (ER) were positive in 13 women in the 5-year relapse-free group vs 8 in locoregional relapse and 7 in bone metastases group (P = 0.032). There were significantly fewer women who received adjuvant chemotherapy in the 5-year relapse-free group than in other two groups (7 vs 23 with locoregional relapse and 25 with bone metastases; P<0.001). This group also had a significantly better 10-year survival (14 women vs 1 with locoregional relapse and 1 with bone metastases; P<0.001). The three groups did not differ in the NY-ESO-1 or HER-2 expression, but the number of patients expressing MAGE-A4 antigen was significantly lower in the group with locoregional relapse (P = 0.014). In all groups, MAGE-A4 antigen expression was associated with the NY-ESO-1 antigen expression (P = 0.006), but not with tumor size and grade, number of metastatically involved axillary lymph nodes, or the ER and PR status. MAGE-A4-positive patients had a significantly longer survival than the MAGE-A4-negative patients (P = 0.046). This was not observed with NY-ESO-1 and HER-2 antigens. Conclusion Our results suggest that the MAGE-A4 antigen may be used as a tumor marker of potential prognostic relevance.


Related Articles

  • Autoantibodies to Tailor-Made Panels of Tumor-Associated Antigens in Breast Carcinoma. Piura, Ettie; Piura, Benjamin // Journal of Oncology;2011, p1 

    Autoantibodies (AAbs) to tumor-associated antigens (TAAs) have been identified in the sera of cancer patients. In a previous review published in this journal, we have focused on recent knowledge related to circulating AAbs to individual TAAs in breast carcinoma. This review will focus on recent...

  • Identificación de los márgenes quirúrgicos mediante mastografía transoperatoria de cuadrantectomías por cáncer de mama y comparación histopatológica. Rita Peña Ayón, Alma; Enrique Mainero Ratchelous, Fernando; Manuel Vargas Solano, Juan; Antonio Buenrostro Pineda, Marco; Bernechea Miranda, Abel; Burgos Portillo, Iván; Israel Aguilar Gallegos, Uriban; Balcázar Rodríguez, Javier // Ginecologia y Obstetricia de Mexico;oct2007, Vol. 75 Issue 10, p588 

    Background: Wide surgical margins are prognostic indicators to prevent recurrences after conservative surgery in breast cancer; type of surgery and histopathological analysis are key factors too. Objectives: To evaluate tumoral size and surgical margins of quadrantectomy specimens utilizing...

  • Breast cancer recurrence: follow up after treatment for primary breast cancer. Hiramanek N // Postgraduate Medical Journal;Mar2004, Vol. 80 Issue 941, p172 

    BACKGROUND: Breast cancer will affect one in 12 Australian women in their lifetime. After potentially curative treatment, it is usual for patients to be followed up for many years. However, controversies surround follow up, and its value is uncertain. AIM: This study reviews the evidence and...

  • Carcinome lobulaire à cellules pléomorphes du sein. Difficultés diagnostiques: à propos d’un cas avec revue de la littérature. Azouz, H.; Bouraoui, S.; Blel, A.; Lahmar, A.; Limaiem, F.; Fadhel, C.; Triki, A.; Gara, F.; Mzabi-Regaya, S. // Oncologie;Nov2008, Vol. 10 Issue 11, p668 

    We report a case of a 27-years-old woman with a lesion at the right breast, incidentally noted. The patient underwent tumour resection followed by a right mastectomy type “Patey”. Microscopic analysis of the tumour had recognised an invasive pleomorphic lobular carcinoma. Invasive...

  • Size, node status and grade of breast tumours: association with mammographic parenchymal patterns. Sala, E.; Solomon, L.; Warren, R.; McCann, J.; Duffy, S.; Luben, R.; Day, N. // European Radiology;Jan2000, Vol. 10 Issue 1, p157 

    A case-control study was designed to assess the association of mammographic parenchymal patterns with the risk of in-situ and invasive breast cancer. In addition, the relationship between tumour characteristics and mammographic patterns were also investigated. A total of 875 patients with breast...

  • "Hippocrates-mst": a prototype for computer-aided microcalcification analysis and risk assessment for breast cancer. Spyrou, George; Kapsimalakou, Smaragda; Frigas, Antonis; Koufopoulos, Konstantinos; Vassilaros, Stamatios; Ligomenides, Panos // Medical & Biological Engineering & Computing;Nov2006, Vol. 44 Issue 11, p1007 

    One of the most common cancer types among women is breast cancer. Regular mammographic examinations increase the possibility for early diagnosis and treatment and significantly improve the chance of survival for patients with breast cancer. Clustered microcalcifications have been considered as...

  • Comparison of early onset breast cancer patients to older premenopausal breast cancer patients. Varga, Dominic; Koenig, Jochem; Kuhr, Kathrin; Strunz, Kathrin; Geyer, Verena; Kurzeder, Christian; Atassi, Ziad; Blettner, Maria; Kreienberg, Rolf; Woeckel, Achim // Archives of Gynecology & Obstetrics;Dec2010, Vol. 282 Issue 4, p427 

    Background: The objective of this study was to show differences between breast cancer patients ≤35 and >35 years with regard to tumor characteristics and to present the patient-relevant outcomes overall survival (OAS) and recurrence-free survival (RFS). Methods: We analyzed data from 119...

  • HER2-negative breast cancer not a risk factor for lower survival.  // Hem/Onc Today;2/25/2008, Vol. 9 Issue 3, p48 

    The article discusses research being done on HER-2 negative breast cancer. It references to a study by M. Brown et al published in a 2008 issue of "Cancer." In the study, the role of HER2 and other demographic and tumor characteristics in survival of women with progesterone receptor-negative...

  • Beating breast cancer. Harrar, Sarí N. // Prevention;Mar2006, Vol. 58 Issue 3, p38 

    This article discusses the increased use of herceptin to treat women with breast cancer. About 1/5 of women with breast cancer produce excessive amounts of the HER-2 protein and herceptin targets this protein. It was previously used only in advanced cases, but is now recommended as standard...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics